Cyclic CRF analogs
AssigneeThe Salk Institute for Biological Studies
InventorsAntonio de Miranda, Wylie W. Vale, Jr., Jean E. F. Rivier, Catherine L. Rivier
Life of this patent
Estimating the term…
Abstract
Improved CRF peptide antagonists have the formula: ##STR1## wherein R.sub.20 is Cys or Glu; R.sub.23 is Cys, Lys or Orn; provided that when R.sub.20 is Cys, R.sub.23 is Cys and when R.sub.20 is Glu, R.sub.23 is Lys or Orn; or a nontoxic addition salt thereof. Specific CRF antagonists disclosed include (cyclo 20-23) [D-Phe.sup.12, Lys.sup.23, Nle.sup.21,38, ]rCRF(12-41); (cyclo 20-23) [D-Phe.sup.12, Orn.sup.23, Nle.sup.21,38 ]rCRF(12-41) and (cyclo 20-23) [D-Phe.sup.12, Cys.sup.20, Cys.sup.23, Nle.sup.21,38 ]rCRF(12-41).
Claims2
A cyclic CRF peptide antagonist having the formula:
- ##STR10##
A CRF cyclic peptide antagonist having the formula:
- ##STR11##
Dependencies are inferred from the claim text.